The effects of ketogenic diet on the Th17/Treg cells imbalance in patients with intractable childhood epilepsy

Seizure. 2016 May:38:17-22. doi: 10.1016/j.seizure.2016.03.006. Epub 2016 Mar 22.

Abstract

Purpose: The ketogenic diet (KD) is an effective treatment for intractable epilepsy (IE), however the therapeutic mechanism is still unclear. This study was designed to investigate T helper type 17/regulatory T cell (Th17/Treg) levels in children with IE and age-matched healthy controls following KD.

Method: Circulating levels of Th17/Treg cells were analyzed by flow cytometry. Plasma concentration of interleukin (IL)-17 was measured by cytometric bead array assay. Real-time PCR was performed to measure mRNA levels of mTOR, HIF1α and Th17/Treg associated factors in purified CD4(+)CD25(+) T and CD4(+)CD25(-) T cells.

Results: By one-way ANOVA, the proportion of circulating Th17 cells and expression of IL-17A and RORγt were significantly higher (P<.05), while the proportion of circulating Tregs and expression of Foxp3, GITR, CTLA-4 were significantly lower (P<.05) in IE patients than healthy subjects. However, these alternations were reversed following KD (P<.05). In CD4(+)CD25(+) T and CD4(+)CD25(-) T cells mTOR and HIF1α expression were significantly higher in IE patients (P<.05), however KD reduced mTOR and HIF1α expression (P<.05). The plasma IL-17A concentrations were higher in IE patients than controls (P<.05). KD partially reduced IL-17A levels (P<.05).

Conclusion: Our results suggest that Th17/Treg imbalance is characteristic of childhood IE, and may contribute to IE pathogenesis. KD treatment is able to correct this imbalance, probably via inhabiting the mTOR/HIF-1α signaling pathway.

Keywords: Intractable epilepsy; Ketogenic diet; Th17 cells; Treg cells.

MeSH terms

  • Child
  • Child, Preschool
  • Diet, Ketogenic / methods*
  • Drug Resistant Epilepsy / blood*
  • Drug Resistant Epilepsy / diet therapy*
  • Female
  • Humans
  • Infant
  • Interleukin-17 / blood*
  • Male
  • T-Lymphocytes, Regulatory*
  • Th17 Cells*
  • Treatment Outcome

Substances

  • IL17A protein, human
  • Interleukin-17